Clinical Development Programme of the Innovative Mesenchymal Stromal Cell Product MSC-FFM/MC0518 for Steroid-Refractory Acute Graft-Versus-Host Disease: Design of 2 Randomised Controlled Trials in Adult and Paediatric Patients
The IDUNN and BALDER trials will deliver definitive evidence on the efficacy and safety of MC0518 in SR-aGvHD and may shape future therapeutic strategies.
Authors
- Uwe Pichlmeier
- Renate von der Weth
- Elena Osswald
- Michael Tribanek
- Robert Zeiser
- Ann-Kristin Möller
- Maria Lazarou-Wild
- Lisa-Marie Pfeffermann
- Halvard Bönig
- Peter Bader
Institutions
- Goethe University Frankfurt (DE)
- University of Freiburg (DE)
- University Medical Center Freiburg (DE)
- German Red Cross (DE)
- Institute for Transfusion Medicine (US)
- Medac (Germany) (DE)
Publication Details
- Journal
- Transfusion Medicine and Hemotherapy
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1159/000550469
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medac